Slide 1: Q4 Report 2024
An entrepreneurial world where people make the difference Bo Annvik, President and CEO Q4 Report 2024 Patrik Johnson, CFO 30 January 2025
Slide 2: Summary 2024
Summary 2024 ▪ Successful 2024 with solid financial performance and strengthened strategic platform, paving the way for continued Net Sales sustainable, profitable growth. ▪ Diversified structure providing resilience in a weaker general business climate. 32.5BSEK ▪ Stable demand situation with 2% to
Slide 3: Highlights fourth quarter 2024
Highlights fourth quarter 2024 ▪ Order intake in line with same period last year, organically a decline of 5%. Net Sales ‒ Organic development mainly explained by strong references linked to large order for pharma production in Denmark ‒ The majority of companies had organic order growth 8.3BSEK ▪ N
Slide 4: Stable underlying order intake and organic sales growth
Stable underlying order intake and organic sales growth Order intake Net Sales MSEK MSEK 9,000 30% 9,000 30% 8,000 25% 8,000 25% 20% 20% 7,000 7,000 15% 15% 6,000 6,000 10% 10% 5,000 5,000 5% 5% 4,000 4,000 0% 0% 3,000 -5% 3,000 -5% 2,000 -10% 2,000 -10% 2020 2021 2022 2023 2024 2020 2021 2022 2023
Slide 5: Organic sales development Q4 – major countries
Organic sales development Q4 – major countries Nordics Rest of Europe Rest of the world Sweden Benelux North America Denmark UK/Ireland Asia Finland Germany Norway Switzerland & Austria Total Nordics Total Rest of Europe Total Rest of the world 5
Slide 6: Net sales per customer segment 2024
Net sales per customer segment 2024 Share of total sales, % ▪ The share of sales within the Medical technology and Medical technology & Pharmaceutical Pharmaceutical segment Infrastructure & Construction continues to climb upwards – up 2 Engineering percentage points since 2023 Process - chemical, p
Slide 7: Stable and high profitability
Stable and high profitability EBITA & EBITA margin Quarterly growth MSEK Q growth 1,400 16% 10% 1,200 15% 8% 7% 6% 1,000 14% 4% 13% 2% 1% 800 0% 12% 0% 600 11% -2% -1% 400 -4% 10% -6% 200 9% -8% 0 8% -10% 2020 2021 2022 2023 2024 Organic Acquisitions Divestments Currency Q EBITA Q EBITA margin Q4-24
Slide 8: Net Sales by Business Area
Net Sales by Business Area Total growth: 2% 0% +20% 9% -1% ▪ A majority of the companies grew organically 10.0% ▪ Strong organic sales growth in Business 8.0% 9% Areas Life Science and Process, Energy & 8% Water 6.0% ▪ Development in Life Science mainly driven by sales Q organic growth 4.0% of MedTe
Slide 9: EBITA margin by Business Area
EBITA margin by Business Area EBITA margin development ▪ Organic sales development and slightly higher expenses are the main drivers of the underlying EBITA margin decline 20% 17.4% 15.6% 16.3% ▪ Good pricing efforts – gross margin 15% 13.6% strengthened to 35.7% (34.8) Q EBITA margin 11.9% ▪ Strong
Slide 10: Acquisitions
Acquisitions Acquisitions 2024 Business Area Annual Sales Acquisitions 2025 pure! GmbH Industrial & Engineering 110 MSEK SDT Scandinavian Drive Technologies AB Industrial & Engineering 55 MSEK Q1 MeHow Medical Ireland Ltd. Life Science 160 MSEK Atline ApS Life Science 60 MSEK Hemomatik AB Technology
Slide 11: Successful acquisition track record
Successful acquisition track record No. of acquired companies per year Quarterly financial effects acquisitions* 18 100 25% 16 90 14 80 20% 70 12 EBITA (MSEK) EBITA margin 60 15% 10 50 8 40 10% 6 30 4 20 5% 2 10 0 0 0% No. of acquired companies No. of acquired companies (3 yr avg) Acquired EBITA Acq
Slide 12: Key data summary
Key data summary MSEK 2024-Q4 2023-Q4 Change 2024 2023 Change Order Intake 8,038 8,044 0% 31,908 31,211 2% Net Sales 8,336 7,821 7% 32,544 31,835 2% Gross margin, % 35.7 34.8 35.0 34.7 EBITA 1,221 1,141 7% 4,689 4,769 -2% EBITA-margin, % 14.6 14.6 14.4 15.0 Net financial items -108 -113 -4% -506 -46
Slide 13: Cash Flow from operating activities
Cash Flow from operating activities Cash Flow development ▪ All-time-high operating cash flow in the MSEK quarter of 1,599 (1,520) MSEK 1,800 160% 1,600 ▪ Main reasons for the high level were 140% 1,400 continued working capital reductions in 120% 1,200 line with last year and slightly higher 100% 1
Slide 14: Earnings per share
Earnings per share EPS development ▪ EPS increased 3% in the quarter to SEK SEK SEK 2.01 (1.95) per share. EPS for the full 2.5 9 year 2024 amounted to SEK 7.55 (7.86) 8 2.0 7 ▪ 3- and 5-year rolling 4Q earnings per 6 share CAGR, were 9% and 13% 1.5 5 4 1.0 3 0.5 2 1 0.0 0 2020 2021 2022 2023 2024 Q
Slide 15: Strong financial position
Strong financial position Net debt development ▪ The interest-bearing net debt declined MSEK sequentially but increased slightly since 12,000 100% same period last year to SEK 8,206 90% 10,000 million (7,747) 80% 8,000 70% ▪ The increase is mainly due to the high 60% acquisition pace in 2024 and sli
Slide 16: Validated climate targets by SBTi
Validated climate targets by SBTi Short term Target year 2030 Scope 1 & 2 Percentage reduction (minimum) 50 %* Scope 3 Percentage reduction 25 %* Long term Target year 2050 Net Zero, percentage reduction Scope 1, 2, 3 90 %* (minimum) 16 *Base year 2023
Slide 17: Key takeaways
Key takeaways ▪ The Indutrade model, based on decentralisation and balanced diversification, shows its strength and is reinforced with the new segment-oriented Group structure. ▪ Stable demand situation in general – continued sales increase and good profit levels. ▪ All-time-high operational cashflo
Slide 18: Thank you!
Thank you! Indutrade
Slide 19: Financial calendar & contact details
Financial calendar & contact details AGM Q1 Report Q2 Report Q3 Report Contact: ir@indutrade.com +46 8 703 03 00
Slide 20: Trusted by entrepreneurs
MT indutrade Trusted by entrepreneurs